Maricann Group Inc. Partners with International Cannabrands Ltd., and Julian Marley to bring JuJu Royal™ Products to Canada and Western Europe
Maricann Announces Appointment of New Chief Financial Officer
Julian Marley’s curated and iconic premium products coming to Canada and Western Europe
exclusively through Maricann.
TORONTO, Ontario (October 6, 2017) – Maricann Group Inc. (CSE:MARI, OTCQB: MRRCF, FRANKFURT: 75M) (“Maricann” or the “Company”), has partnered with Julian Marley and International Cannabrands Ltd. (“International Cannabrands”) a wholly owned subsidiary of GEA Technologies Ltd. (CSE:JUJU.A) to cultivate and formulate JuJu Royal™, a premium and market established group of products. Julian, son of the iconic Bob Marley, is a true and authentic representation of Rasta culture. A world renowned reggae artist and devoted Rastafarian, Julian conveys his message of legalization, freedom and love through his music, and the JuJu Royal brand.
Maricann Revises Convertible Debenture Terms
TORONTO, Ontario (October 3, 2017) – Maricann Group Inc. (CSE: MARI, OTCQB: MRRCF, FRA: 75M) (“Maricann” or the “Company”) is pleased to announce the appointment of Scott Langille as the Company’s Chief Financial Officer effective October 2, 2017, subject to regulatory approval.
Maricann Group Inc. Secures Second-Site Sales Licence in Canada
TORONTO, Ontario, September 21, 2017 – Maricann Group Inc. (CSE:MARI “Maricann” or the “Company”) announces that it has amended the terms of its previously announced private placement (the “Offering”) of convertible debenture units (the “Convertible Debenture Units”). The Company will now issue up to $20,000,000 aggregate principal amount of Convertible Debenture Units pursuant to the Offering at a price of $1,000 per Convertible Debenture Unit.
Maricann Group Inc. Provides Operational Update
TORONTO, Ontario, September 5, 2017 – Maricann Group Inc. (CSE:MARI) (“Maricann” or the “Company”) announced today that it has secured a second-site sales licence for its location in Burlington, ON Canada through its wholly owned subsidiary Maricann Inc. The sales licence is the second granted to Maricann by Health Canada, with the first applying to the company’s cultivation and processing facility in Langton, ON. With the granting of the new licence, Maricann is shifting its client services, sales operations and research activities to Burlington.
Maricann Group Inc. Announces Private Placement of up to $35 Million of Convertible Debenture Units
TORONTO, Sept. 5, 2017— Maricann Group Inc. (CSE:MARI) ("Maricann" or the "Company") a low cost, greenhouse producer of medical cannabis with market leading technological differentiation, is providing this operational update. On March 8th, a windstorm with gale forces up to 115 kph hit the peninsula on the shores of Lake Erie near the Company’s Langton, Ontario site. An unusual event, the storm resulted in sand and foreign materials from nearby fields being blown into two of the Company’s five main flowering greenhouses.
Maricann Group Inc. Announces Acquisition of NanoLeaf Technologies Inc., Appoints New President and Chief Operating Officer
Maricann Group Inc. (CSE:MARI) (“Maricann” or the “Company”) announced today that it has entered into an agreement with Canaccord Genuity Corp., as lead agent on behalf of a syndicate of investment dealers, including Industrial Alliance Securities Inc., Mackie Research Capital Corporation and Sprott Capital Partners (collectively, the “Agents”) pursuant to which the Company will issue on a private placement basis up to $35,000,000 aggregate principal amount of convertible debenture units (the “Convertible Debenture Units”) at a price of $1,000 per Convertible Debenture Unit.
In a crowding market, seek differentiation
TORONTO, ONTARIO--(Marketwired - Aug. 22, 2017) - Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI) ("Maricann" or the "Company") announced today that it has entered into an agreement ("Acquisition Agreement") to acquire 100% of the issued and outstanding shares of NanoLeaf Technologies Inc. ("NanoLeaf"), a biotech company possessing licensing rights to a number of globally patented technologies that provide proven pharmaceutical, nutraceutical, cosmetic and functional beverage drug delivery formulations. The transaction is expected to be completed by the end of September 2017.
Maricann Group Inc. Enters Into Letter of Intent
Health Canada stokes already heated competition. Recent results suggest that many LPs have struggled to ramp production and have therefore missed consensus expectations for sales volumes. While such growing pains are to be expected, on the positive side, quarterly earnings also suggest that cannabis prices have climbed higher due to supply constraints. Read more from Canaccord Genuity on how Maricann is positioned to be a meaningful low-cost producer in Canada.
Forget the US. Here’s where medical marijuana is really taking off
TORONTO, Ontario, Aug. 16, 2017 – Maricann Group Inc. (CSE:MARI) (“Maricann” or the “Company”) and a national provider that services pharmacies across Canada (the “Counterparty”), have agreed to a primary collaborative partnership through a joint initiative to create a pharmacy services program that enables pharmacists to counsel and appropriately educate patients in relation to medicinal cannabis.
Maricann Looks To Replicate Canada Success In Newly Legal German Cannabis Market
There's a groundswell of support for cannabis legalisation in the United States, with 29 states, as well as Washington D.C. approved for medicinal cannabis, and eight for lifestyle use.
Things are farther ahead in Canada. Regulations for production and sales have been in place for over three years, and the federal government has introduced a timeline to full federal legalisation for lifestyle use in July 2018. Capacity in Canada for lifestyle alone is projected to reach "5 billion dollars per year to start," according to a recent report from Deloitte.
Maricann CEO Talks C$42.5M Financing Round And German Expansion: 'We Are In A Pole Position'
Anyone looking for a model company in the medical cannabis sector would be well advised to consider Maricann Group Inc (CSE:MARI), as thus far it seems to have done everything right.
With a green ethos that drives both product development and corporate efficiency efforts, Maricann succeeded in becoming one of the first companies in Canada approved to cultivate and sell medical cannabis.
Not content with being an early mover in just its home market, Maricann was quick to stake its claim in another jurisdiction largely overlooked by its peers: Germany.
Javier Hasse, Benzinga, June 14, 2017
Last month, Maricann Group Inc. (CSE:MARI), a vertically integrated medical marijuana producer and distributor, announced it had secured C$42.5 million, or $32.2 million, in non-dilutive financing to increase production in Germany.
This raise was one of the biggest of 2017 and Benzinga reached out to the company’s CEO Ben Ward to chat about the business and the recent developments.